Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $66.00 Average Target Price from Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned an average rating of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $66.00.

Several equities research analysts have recently weighed in on MAZE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Insider Activity

In other Maze Therapeutics news, CEO Jason Coloma sold 11,411 shares of Maze Therapeutics stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the transaction, the chief executive officer directly owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. The trade was a 29.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $26.22, for a total value of $254,465.10. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 219,317 shares of company stock valued at $5,989,040 in the last ninety days. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics during the 4th quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics during the 2nd quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. increased its stake in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.

Maze Therapeutics Trading Down 0.9%

MAZE stock opened at $24.60 on Friday. The firm has a fifty day moving average price of $28.20 and a 200 day moving average price of $30.46. Maze Therapeutics has a fifty-two week low of $22.01 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market cap of $1.37 billion, a PE ratio of -9.76 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Sell-side analysts anticipate that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.